Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Boule Diagnostics AB ( (SE:BOUL) ) has shared an update.
Boule Diagnostics announced the departure of its Chief Financial Officer, Holger Lembrér, who will leave the company to pursue a new professional opportunity. CEO Torben Nielsen expressed gratitude for Lembrér’s leadership, which has been crucial during the company’s growth and transformation. Lembrér will remain in his role for six months to ensure a smooth transition, while the company searches for a successor.
More about Boule Diagnostics AB
Boule Diagnostics AB is a global diagnostics company specializing in near-patient, decentralized blood diagnostics. It is one of the few companies in the global diagnostics market that conducts its own development, manufacturing, and marketing of instruments and consumables for blood diagnostics. The company primarily serves hospitals, clinics, laboratories, and other diagnostics companies, offering complete systems for blood diagnostics in both human and veterinary areas. Boule has strong positions in emerging markets such as Asia and has improved its position in the veterinary market. Operations are conducted through subsidiaries in Sweden, the United States, Mexico, and Russia, with sales in over 100 countries. Boule has been listed on Nasdaq Stockholm since 2011.
Average Trading Volume: 72,270
Current Market Cap: SEK197.3M
See more data about BOUL stock on TipRanks’ Stock Analysis page.